Oxford BioMedica PLC
Medawar Centre<br>Robert Robinson Avenue
The Oxford Science Park
154 articles with Oxford BioMedica PLC
Companies are still developing and refining treatments and preventions for COVID-19, but not all of them are approved or authorized. Here’s a look at the latest COVID-19 news.
Oxford Biomedica plc, a leading cell and gene therapy group, announces its preliminary results for the year ended 31 December 2021.
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc.
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
Homology Medicines, Inc., a genetic medicines company, announced the successful closing of the deal with Oxford Biomedica plc to establish an Adeno-Associated Virus Manufacturing and Innovation Business.
The FDA asked Homology Medicines to modify the pheNIX gene therapy trial's risk mitigation measures to prevent any serious issues that may arise.
Oxford Biomedica plc announced today that it was informed on Monday 31 January by Sio Gene Therapies (Sio) that Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease.
Oxford BioMedica and Homology Medicines have formed a symbiotic partnership to launch a full scope AAV manufacturing and innovation business.
Virica Biotech Announces R&D Partnership With Oxford Biomedica to Improve the Manufacturing of Lentiviral Vector Gene Therapies Using Viral Sensitizers
Virica Biotech Inc. today announced it will collaborate with Oxford Biomedica plc to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers ( VSEs™ ).
Oxford Biomedica plc a leading gene and cell therapy company, announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from the Company.
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium and Oxford Biomedica, announced that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners to progress and further accelerate the development of a potential, new treatment option for patients with CF.
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
Oxford Biomedica plc, a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group’s Board as a Non-Executive Director
Papyrus Therapeutics, Inc. (“Papyrus” or the “Company”), an emerging biopharma company developing novel extracellular tumor suppressor therapies for the treatment of cancer and Oxford Biomedica plc (LSE:OXB or the “Group”), a leading gene and cell therapy group, announced today the signing of a research collaboration agreement. The collaboration includes the assessment of the impact and therapeutic benefit of Papyr
Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD
Axovant Gene Therapies Ltd, a clinical-stage company developing innovative gene therapies for neurological diseases, announced that its subsidiary has signed a three-year Clinical Supply Agreement with Oxford Biomedica plc, a leading gene and cell therapy group.
Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a one year Clinical & Commercial Supply Agreement with AstraZeneca UK Ltd (“AstraZeneca”).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Oxford Biomedica and Santen enter R&D collaboration and Option & Licence Agreement for development of gene therapy vectors for inherited retinal disease
Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd. (Santen), the market leader for prescription ophthalmic pharmaceuticals in Japan with a global presence in over 60 countries, today announced that they have entered into an R&D collaboration and Option & Licence Agreement to research and develop gene therapy products for the treatment of an inherited retinal disease
Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings’ agreement to subscribe for 6,568,024 new ordinary shares in OXB (the “Subscription Shares”) at a price of £6.90 per share (the “Subscription Price”),
Oxford Biomedica plc (LSE:OXB) (“OXB” or “the Group”), a leading gene and cell therapy group, today announces that Novo Holdings A/S (“Novo Holdings”), has agreed to invest up to £53.5 million in the Group in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase (the “Transaction”).
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.